On April 29, 2016, YaoPharma held the 2015 annual shareholder meeting, and the 17th meeting of the 7th session of the board.

12 resolutions were passed during the meeting, including the “2015 Annual Work Report of the Board” and “2015 Annual Work Report of the President”. “2015 Annual Finance Statements and 2016 Annual Budget Report”.

Facing with China's economic slowdown and the “New Normal” of more intense competition among enterprises due to accelerated reform of pharmaceutical industry, under the leadership of the board of directors, the management team led the company to a new height by setting internationalization as the main strategy and product + talents as the driving force, and enhancing reform and innovation. The board of shareholders, board of directors and board of supervisors acknowledged YaoPharma’s accomplishments in 2015. At the same time, they also provided suggestions and made new requests for 2016. We should not only focus on endogenous innovation and tapping the potential of the traditional industry, but we also need to accelerate industrial upgrading, cultivate and develop new growth points, to create "double drive", "new potentials, and release " new energy ", realize sustainable and leap forward development, opening a new chapter of development.